ReviewThe Journal of clinical and aesthetic dermatology2023
Is There a Clinically Relevant Risk of Hyperkalemia with Topical Clascoterone Treatment?
Review in The Journal of clinical and aesthetic dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Clascoterone in the Treatment of Acne Vulgaris: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Hyperkalemia in Severe Burn Injuries: Pathogenesis and Therapeutic Advances.Journal of community hospital internal medicine perspectives · 2026Review
- A Comprehensive Review of Electrolyte Imbalances and Their Applied Aspects in Dermatology.Cureus · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clascoterone cream 1% is an androgen receptor inhibitor approved for the treatment of acne vulgaris in patients aged 12 years or older with clinical studies completed in subjects aged nine years or older. Blood potassium levels above the upper limit of normal (i.e., hyperkalemia) were reported in both clascoterone-treated and vehicle-treated patients; reported rates of hyperkalemia were approximately five percent and four percent, respectively. None of the cases of hyperkalemia were reported as adverse events and none led to study discontinuation or adverse clinical sequelae. An exposure-response analysis showed no correlation between plasma concentrations of clascoterone or its metabolite cortexolone and cases of hyperkalemia. Based on the laboratory safety profile of clascoterone demonstrated in the Phase I and Phase II studies, baseline or subsequent laboratory monitoring was not required in the Phase III studies or recommended in the FDA-approved prescribing information. The frequency of shifts to elevated potassium levels was highest in patients younger than 12 years of age treated with clascoterone, for whom clascoterone 1% is not FDA approved.
Indexed as
Identifiers
37361363PMC10286882W4382182597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.